Filed pursuant to Rule 424(b)(5)

Registration No. 333-239751

 

PROSPECTUS SUPPLEMENT (TO PROSPECTUS SUPPLEMENT DATED OCTOBER 13, 2020)

 

VXRT20210914_424B5IMG001.GIF

 

 

VAXART, INC.

Common Stock

 

This prospectus supplement amends, supplements, and supersedes our prospectus supplement dated October 13, 2020 related to an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC and Piper Sandler & Co., and should be read together with the accompanying prospectus dated July 8, 2020.

 

Effective September 13, 2021, we terminated the Sales Agreement and discontinued all offers and sales of our common stock, par value $0.0001 per share, thereunder. Between July 8, 2020, the date of the Sales Agreement, and September 13, 2021, we sold an aggregate of 13,932,490 shares of common stock pursuant to the Sales Agreement for aggregate gross proceeds of approximately $133.4 million.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

Jefferies  Piper Sandler

The date of this prospectus supplement is September 15, 2021

 
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vaxart Charts.
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vaxart Charts.